Lambert, J., C. Paul, A. Gottlieb, and Y. Poulin. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Analysis of Body Surface Area Involvement in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s45, doi:10.25251/skin.6.supp.45.